Spotlight
Clinical
Events
CME
Partners
Subscribe
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
OPKO Health acquires company
OPKO Health has acquired Vidus Ocular, a privately held company developing a shunt (Aquashunt) to treat glaucoma.
Miami-OPKO Health has acquired Vidus Ocular, a privately held company developing a shunt (Aquashunt) to treat glaucoma.
The patented device was designed by M. Bruce Shields, MD, chairman emeritus, Department of Ophthalmology and Visual Science, Yale University School of Medicine. Dr. Shields is chief scientific and medical officer at Vidus Ocular.
"Preclinical data on the device are encouraging, and we believe that OPKO is an ideal partner to assume responsibility for the development and commercialization of this potentially important product," he said.
Related Videos
Related Content
